References

References1.Toofanny N, Maddens ME, Voytas J, et al. Low bone mass and postfall fracture risk among elderly nursing home men. J Am Med Dir Assoc 2004;5:367–370.ToofannyN]]MaddensME]]VoytasJ&etal;Low bone mass and postfall fracture risk among elderly nursing home men.J Am Med Dir Assoc20045367-3702.Zimmerman SI, Girman CJ, Buie VC, et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 1999;9:151–157.ZimmermanSI]]GirmanCJ]]BuieVC&etal;The prevalence of osteoporosis in nursing home residents.Osteoporos Int19999151-1573.Sallin U, Mellström D, Eggertsen R. Osteoporosis in a nursing home, determined by the DEXA technique. Med Sci Monit 2005;11:CR67–CR70.SallinU]]MellströmD]]EggertsenROsteoporosis in a nursing home, determined by the DEXA technique.Med Sci Monit200511CR67-CR704.Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–475.5.Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997;45:281–287.BrainskyA]]GlickH]]LydickE&etal;The economic cost of hip fractures in community-dwelling older adults: a prospective study.J Am Geriatr Soc199745281-2876.Department of Health and Human Services. Available at: www.surgeongeneral.com/library/bonehealth. Accessed April 20, 2008.7.Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799–1809.LylesKW]]Colón-EmericCS]]MagazinerJS&etal;Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med20073571799-18098.Colón-Emeric C, Lyles KW, Levine DA, et al. Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 2007;18:553–559.Colón-EmericC]]LylesKW]]LevineDA&etal;Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture.Osteoporos Int200718553-5599.National Osteoporosis Foundation. Available at: http://www.nof.org/news/pressreleases/Clinician_Guide_release.htm. Accessed June 2, 2008.10.Rojas-Fernandez CH, Lapane KL, MacKnight C, et al. Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database. Endocr Pract 2002;8:335–342.Rojas-FernandezCH]]LapaneKL]]MacKnightC&etal;Undertreatment of osteoporosis in residents of nursing homes: population-based study with use of the Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) database.Endocr Pract20028335-34211.Wright RM. Use of osteoporosis medications in older nursing facility residents. J Am Med Dir Assoc 2007;8:453–457.WrightRMUse of osteoporosis medications in older nursing facility residents.J Am Med Dir Assoc20078453-45712.Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637–1642.ChapuyMC]]ArlotME]]DuboeufF&etal;Vitamin D3 and calcium to prevent hip fractures in the elderly women.N Engl J Med19923271637-164213.Sato Y, Iwamoto J, Kanoko T, et al. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005;165:1743–1748.SatoY]]IwamotoJ]]KanokoT&etal;Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.Arch Intern Med20051651743-174814.Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811–816.SatoY]]IwamotoJ]]KanokoT&etal;Risedronate therapy for prevention of hip fracture after stroke in elderly women.Neurology200564811-81615.Jachna CM, Shireman TI, Whittle J, et al. Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers. J Am Geriatr Soc 2005;53:1275–1281.JachnaCM]]ShiremanTI]]WhittleJ&etal;Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers.J Am Geriatr Soc2005531275-128116.Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375–382.KanisJA]]JohnellO]]De LaetC&etal;A meta-analysis of previous fracture and subsequent fracture risk.Bone200435375-38217.Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721–739.KlotzbuecherCM]]RossPD]]LandsmanPB&etal;Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.J Bone Miner Res200015721-73918.Berry SD, Samelson EJ, Hannan MT, et al. Second hip fracture in older men and women: the Framingham Study. Arch Intern Med 2007;167:1971–1976.BerrySD]]SamelsonEJ]]HannanMT&etal;Second hip fracture in older men and women: the Framingham Study.Arch Intern Med20071671971-197619.Egan M, Jaglal S, Byrne K, et al. Factors associated with a second hip fracture: a systematic review. Clin Rehabil 2008;22:272–282.EganM]]JaglalS]]ByrneK&etal;Factors associated with a second hip fracture: a systematic review.Clin Rehabil200822272-28220.Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of fracture in white female nursing home residents. JAMA 2000;284:972–977.ChandlerJM]]ZimmermanSI]]GirmanCJ&etal;Low bone mineral density and risk of fracture in white female nursing home residents.JAMA2000284972-97721.Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007;297:387–394.CenterJR]]BliucD]]NguyenTV&etal;Risk of subsequent fracture after low-trauma fracture in men and women.JAMA2007297387-39422.Melton LJ III, Ilstrup DM, Beckenbaugh RD, et al. Hip fracture recurrence. A population-based study. Clin Orthop Relat Res 1982:131–138.MeltonLJIII]]IlstrupDM]]BeckenbaughRD&etal;Hip fracture recurrence. A population-based study.Clin Orthop Relat Res1982&NA;131-13823.Kiely DK, Kiel DP, Burrows AB, et al. Identifying nursing home residents at risk for falling. J Am Geriatr Soc 1998;46:551–555.KielyDK]]KielDP]]BurrowsAB&etal;Identifying nursing home residents at risk for falling.J Am Geriatr Soc199846551-55524.Levencron S, Kimyagarov S. [Frequency and reasons for falling among residents of the geriatric center]. Harefuah 2007;146:589–593, 647.LevencronS]]KimyagarovS[Frequency and reasons for falling among residents of the geriatric center].Harefuah2007146589-593, 64725.Kamel HK. Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc 2007;8:434–440.KamelHKUpdate on osteoporosis management in long-term care: focus on bisphosphonates.J Am Med Dir Assoc20078434-44026.Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385–397.KanisJA]]JohnellO]]OdenA&etal;FRAX and the assessment of fracture probability in men and women from the UK.Osteoporos Int200819385-39727.Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449–458.Dawson-HughesB]]TostesonAN]]MeltonLJIII&etal;National Osteoporosis Foundation Guide CommitteeImplications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.Osteoporos Int200819449-45828.Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477–501.LipsPVitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.Endocr Rev200122477-50129.Visser M, Deeg DJ, Puts MT, et al. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006;84:616–622; quiz 671–672.30.Byszewski AM, Cranney A, Man-Son-Hing M, et al. Evaluation of in-hospital management of fracture risk in older patients: a chart review study of tertiary prevention. Arch Gerontol Geriatr 2006;42:319–328.ByszewskiAM]]CranneyA]]Man-Son-HingM&etal;Evaluation of in-hospital management of fracture risk in older patients: a chart review study of tertiary prevention.Arch Gerontol Geriatr200642319-32831.Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670–676.Dawson-HughesB]]HarrisSS]]KrallEA&etal;Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.N Engl J Med1997337670-67632.Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004;19:370–378.LarsenER]]MosekildeL]]FoldspangAVitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study.J Bone Miner Res200419370-37833.Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657–666.TangBM]]EslickGD]]NowsonC&etal;Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.Lancet2007370657-66634.Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005;3:CD000227.AvenellA]]GillespieWJ]]GillespieLD&etal;Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.Cochrane Database Syst Rev20053CD00022735.Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257–2264.Bischoff-FerrariHA]]WillettWC]]WongJB&etal;Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials.JAMA20052932257-226436.Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560–569.PapadimitropoulosE]]WellsG]]SheaB&etal;Meta-analyses of therapies for postmenopausal osteoporosis VIII: meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women.Endocr Rev200223560-56937.Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124:400–406.LipsP]]GraafmansWC]]OomsME&etal;Vitamin D supplementation and fracture incidence in elderly persons A randomized, placebo-controlled clinical trial.Ann Intern Med1996124400-40638.Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992;51:105–110.HeikinheimoRJ]]InkovaaraJA]]HarjuEJ&etal;Annual injection of vitamin D and fractures of aged bones.Calcif Tissue Int199251105-11039.Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–683.JacksonRD]]LaCroixAZ]]GassM&etal;Calcium plus vitamin D supplementation and the risk of fractures.N Engl J Med2006354669-68340.Flicker L, Mead K, MacInnis RJ, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003;51:1533–1538.FlickerL]]MeadK]]MacInnisRJ&etal;Serum vitamin D and falls in older women in residential care in Australia.J Am Geriatr Soc2003511533-153841.Bischoff HA, Stähelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343–351.BischoffHA]]StähelinHB]]DickW&etal;Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial.J Bone Miner Res200318343-35142.Harwood RH, Sahota O, Gaynor K, et al; The Nottingham Neck of Femur (NONOF) Study. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study. Age Ageing 2004;33:45–51.HarwoodRH]]SahotaO]]GaynorK&etal;The Nottingham Neck of Femur (NONOF) StudyA randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham Neck of Femur (NONOF) Study.Age Ageing20043345-5143.Broe KE, Chen TC, Weinberg J, et al. A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc 2007;55:234–239.BroeKE]]ChenTC]]WeinbergJ&etal;A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study.J Am Geriatr Soc200755234-23944.Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–281.HolickMFVitamin D deficiency.N Engl J Med2007357266-28145.Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997;7:439–443.ChapuyMC]]PreziosiP]]MaamerM&etal;Prevalence of vitamin D insufficiency in an adult normal population.Osteoporos Int19977439-44346.Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215–3224.HolickMF]]SirisES]]BinkleyN&etal;Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.J Clin Endocrinol Metab2005903215-322447.Gertner JM, Domenech M. 25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol. J Clin Pathol 1977;30:144–150.GertnerJM]]DomenechM25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol.J Clin Pathol197730144-15048.Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842–856.ViethRVitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.Am J Clin Nutr199969842-85649.Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.TrivediDP]]DollR]]KhawKTEffect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.BMJ200332646950.Aloia JF, Patel M, Dimaano R, et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008;87:1952–1958.AloiaJF]]PatelM]]DimaanoR&etal;Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration.Am J Clin Nutr2008871952-195851.Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387–5391.ArmasLA]]HollisBW]]HeaneyRPVitamin D2 is much less effective than vitamin D3 in humans.J Clin Endocrinol Metab2004895387-539152.Przybelski R, Agrawal S, Krueger D, et al. Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int 2008;19:1621–1628.PrzybelskiR]]AgrawalS]]KruegerD&etal;Rapid correction of low vitamin D status in nursing home residents.Osteoporos Int2008191621-162853.Grey A, Lucas J, Horne A, et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005;90:2122–2126.GreyA]]LucasJ]]HorneA&etal;Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency.J Clin Endocrinol Metab2005902122-212654.Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 2008;93:677–681.HolickMF]]BiancuzzoRM]]ChenTC&etal;Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D.J Clin Endocrinol Metab200893677-68155.Kanis JA, Melton LJ III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994:1137–1141.KanisJA]]MeltonLJIII]]ChristiansenC&etal;The diagnosis of osteoporosis.J Bone Miner Res1994&NA;1137-114156.Marks R, Allegrante JP, Ronald MacKenzie C, et al. Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev 2003;2:57–93.MarksR]]AllegranteJP]]Ronald MacKenzieC&etal;Hip fractures among the elderly: causes, consequences and control.Ageing Res Rev2003257-9357.Suzuki T, Kim H, Yoshida H, et al. Randomized controlled trial of exercise intervention for the prevention of falls in community-dwelling elderly Japanese women. J Bone Miner Metab 2004;22:602–611.SuzukiT]]KimH]]YoshidaH&etal;Randomized controlled trial of exercise intervention for the prevention of falls in community-dwelling elderly Japanese women.J Bone Miner Metab200422602-61158.Stevens JA, Olson S. Reducing falls and resulting hip fractures among older women. MMWR Recomm Rep 2000;49:3–12.StevensJA]]OlsonSReducing falls and resulting hip fractures among older women.MMWR Recomm Rep2000493-1259.Kita K, Hujino K, Nasu T, et al. A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease. Osteoporos Int 2007;18:611–619.KitaK]]HujinoK]]NasuT&etal;A simple protocol for preventing falls and fractures in elderly individuals with musculoskeletal disease.Osteoporos Int200718611-61960.Walker M, Klentrou P, Chow R, et al. Longitudinal evaluation of supervised versus unsupervised exercise programs for the treatment of osteoporosis. Eur J Appl Physiol 2000;83:349–355.WalkerM]]KlentrouP]]ChowR&etal;Longitudinal evaluation of supervised versus unsupervised exercise programs for the treatment of osteoporosis.Eur J Appl Physiol200083349-35561.Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women study of Osteoporotic Fractures Research Group. Ann Intern Med 1998;129:81–88.GreggEW]]CauleyJA]]SeeleyDG&etal;Physical activity and osteoporotic fracture risk in older women study of Osteoporotic Fractures Research Group.Ann Intern Med199812981-8862.Fiatarone MA, O’Neill EF, Ryan ND, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994;330:1769–1775.FiataroneMA]]O’NeillEF]]RyanND&etal;Exercise training and nutritional supplementation for physical frailty in very elderly people.N Engl J Med19943301769-177563.Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA 1995;273:1341–1347.ProvinceMA]]HadleyEC]]HornbrookMC&etal;The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials Frailty and Injuries: Cooperative Studies of Intervention Techniques.JAMA19952731341-134764.Evans WJ. Effects of exercise on body composition and functional capacity of the elderly. J Gerontol A Biol Sci Med Sci 1995;50:147–150.EvansWJEffects of exercise on body composition and functional capacity of the elderly.J Gerontol A Biol Sci Med Sci199550147-15065.Donald IP, Pitt K, Armstrong E, et al. Preventing falls on an elderly care rehabilitation ward. Clin Rehabil 2000;14:178–185.DonaldIP]]PittK]]ArmstrongE&etal;Preventing falls on an elderly care rehabilitation ward.Clin Rehabil200014178-18566.Mulrow CD, Gerety MB, Kanten D, et al. A randomized trial of physical rehabilitation for very frail nursing home residents. JAMA 1994;271:519–524.MulrowCD]]GeretyMB]]KantenD&etal;A randomized trial of physical rehabilitation for very frail nursing home residents.JAMA1994271519-52467.Nowalk M, Prendergast JM, Bayles CM, et al. A randomized trial of exercise programs among older individuals living in two long-term care facilities: the FallsFREE program. J Am Geriatr Soc 2001;49:859–865.NowalkM]]PrendergastJM]]BaylesCM&etal;A randomized trial of exercise programs among older individuals living in two long-term care facilities: the FallsFREE program.J Am Geriatr Soc200149859-86568.Greenspan SL, Myers ER, Kiel DP, et al. Fall direction, bone mineral density, and function: risk factors for hip fracture in frail nursing home elderly. Am J Med 1998;104:539–545.GreenspanSL]]MyersER]]KielDP&etal;Fall direction, bone mineral density, and function: risk factors for hip fracture in frail nursing home elderly.Am J Med1998104539-54569.Laing AC, Robinovitch SN. Effect of soft shell hip protectors on pressure distribution to the hip during sideways falls. Osteoporos Int 2008;19:1067–1075.LaingAC]]RobinovitchSNEffect of soft shell hip protectors on pressure distribution to the hip during sideways falls.Osteoporos Int2008191067-107570.Parker MJ, Gillespie WJ, Gillespie LD. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2005;3:CD001255.ParkerMJ]]GillespieWJ]]GillespieLDHip protectors for preventing hip fractures in older people.Cochrane Database Syst Rev20053CD00125571.Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007;298:413–422.KielDP]]MagazinerJ]]ZimmermanS&etal;Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial.JAMA2007298413-42272.Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–1541.BlackDM]]CummingsSR]]KarpfDB&etal;Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.Lancet19963481535-154173.Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.WellsGA]]CranneyA]]PetersonJ&etal;Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev20081CD00115574.Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD004523.WellsG]]CranneyA]]PetersonJ&etal;Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.Cochrane Database Syst Rev20081CD00452375.Borgström F, Carlsson A, Sintonen H, et al. The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 2006;17:996–1007.BorgströmF]]CarlssonA]]SintonenH&etal;The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.Osteoporos Int200617996-100776.Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006;166:1209–1217.LiuH]]MichaudK]]NayakS&etal;The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.Arch Intern Med20061661209-121777.Mobley LR, Hoerger TJ, Wittenborn JS, et al. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making 2006;26:194–206.MobleyLR]]HoergerTJ]]WittenbornJS&etal;Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.Med Decis Making200626194-20678.Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18:1047–1061.StrömO]]BorgströmF]]SenSS&etal;Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries—an economic evaluation based on the fracture intervention trial.Osteoporos Int2007181047-106179.Chesnut IC III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.ChesnutICIII]]SkagA]]ChristiansenC&etal;Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.J Bone Miner Res2004191241-124980.Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1822.BlackDM]]DelmasPD]]EastellR&etal;Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med20073561809-182281.Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792–798.DelmasPD]]ReckerRR]]ChesnutCHIII&etal;Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.Osteoporos Int200415792-79882.McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group. N Engl J Med 2001;344:333–340.McClungMR]]GeusensP]]MillerPD&etal;Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group.N Engl J Med2001344333-34083.Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003;62:969–975.StakkestadJA]]BenevolenskayaLI]]StepanJJ&etal;Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.Ann Rheum Dis200362969-97584.Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826–831.HeckbertSR]]LiG]]CummingsSR&etal;Use of alendronate and risk of incident atrial fibrillation in women.Arch Intern Med2008168826-83185.Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–1301.OdvinaCV]]ZerwekhJE]]RaoDS&etal;Severely suppressed bone turnover: a potential complication of alendronate therapy.J Clin Endocrinol Metab2005901294-130186.Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005;20:2105–2115.MillerPD]]RouxC]]BoonenS&etal;Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.J Bone Miner Res2005202105-211587.McDermott RS, Kloth DD, Wang H, et al. Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model. J Support Oncol 2006;4:524–529.McDermottRS]]KlothDD]]WangH&etal;Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model.J Support Oncol20064524-52988.Actonel Package Insert. Cincinnati, OH, Procter and Gamble Pharmaceuticals, 2006.&NA;Actonel Package Insert.Cincinnati, OHProcter and Gamble Pharmaceuticals200689.Boniva [Package Insert]. Nutley, NJ, Roche Laboratories Inc, 2006.&NA;Boniva [Package Insert].Nutley, NJRoche Laboratories Inc200690.Fosamax (Alendronate) [Package Insert]. Whitehouse Station, NJ, Merck & Co, Inc, 2007.&NA;Fosamax (Alendronate) [Package Insert].Whitehouse Station, NJMerck & Co, Inc200791.Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007;20:186–190.MillerPDIs there a role for bisphosphonates in chronic kidney disease?Semin Dial200720186-19092.Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.NeerRM]]ArnaudCD]]ZanchettaJR&etal;Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med20013441434-144193.Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528–4535.BodyJJ]]GaichGA]]ScheeleWH&etal;A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis.J Clin Endocrinol Metab2002874528-453594.Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024–2030.LindsayR]]ScheeleWH]]NeerR&etal;Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.Arch Intern Med20041642024-203095.Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507–1513.PrinceR]]SiposA]]HossainA&etal;Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.J Bone Miner Res2005201507-151396.Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–1215.BlackDM]]GreenspanSL]]EnsrudKE&etal;The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.N Engl J Med20033491207-121597.Finkelstein JS, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216–1226.FinkelsteinJS]]GreenspanSL]]EnsrudKE&etal;The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.N Engl J Med20033491216-122698.Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745–751.EttingerB]]San MartinJ]]CransG&etal;Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.J Bone Miner Res200419745-75199.Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998;13:1051–1055.CosmanF]]NievesJ]]WoelfertL&etal;Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.J Bone Miner Res1998131051-1055100.Deal C, Gideon J. Recombinant human PTH 1–34 (Forteo): an anabolic